Develops DNA medicines for HPV-associated diseases and cancer.
Jun 2026Revenue $0.00/yrExpenses $79.3M/yr
No trendCash runway ≈ 5 months from Jun 2026
Figures by year
When will Inovio Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $79.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $65.3K | $86.9M | −$86.8M |
| Dec 2024 | $218K | $113M | −$112M |
| Dec 2023 | $832K | $145M | −$144M |
| Dec 2022 | $10.3M | $278M | −$268M |
| Dec 2021 | $1.77M | $303M | −$301M |
| Dec 2020 | $7.41M | $131M | −$124M |
| Dec 2019 | $4.11M | $115M | −$111M |
| Dec 2018 | $30.5M | $125M | −$94.1M |
| Dec 2017 | $42.2M | $126M | −$83.6M |
| Dec 2016 | $35.4M | $112M | −$76.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.